

Note to Readers: *In the event of any inconsistency between this document and the legislation that governs chiropractic and naturopathic practice in Nova Scotia, the legislation prevails.*

1. INTRODUCTION

The Nova Scotia Chiropractic and Naturopathic Regulator (NSCNR) is the regulatory authority for the practice of chiropractic and naturopathy in the Province of Nova Scotia.

This Standard of Practice establishes the minimum requirements for Registrants holding an active licence with the NSCNR who obtain, store, handle, select, dispense, provide, document, or maintain traceability for substances and/or drugs used in-office as part of an authorized clinical procedure.

For the purposes of this Standard, **dispensing is limited to substances and/or drugs that are administered directly to a patient in-office by the Registrant as part of a patient encounter.**

This Standard applies to substances and/or drugs used in authorized naturopathic procedures, including procedures performed under a Reserved Practice Permit such as Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, and Autologous Blood Products.

Where a dispensed substance or drug is accessed, mixed, diluted, combined, transferred, or otherwise prepared in a manner that constitutes immediate-use compounding or aseptic preparation of sterile products, the ND Registrant must also comply with the NSCNR Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products.

For clarity, this Standard governs in-office dispensing, procurement, storage, handling, traceability, and documentation. It does not independently authorize the administration of any drug, substance, injection, infusion, ozone therapy, oxidative therapy, autologous blood product, or other Reserved Practice unless the Registrant holds the required authority, training, competence, and permit for that activity.

2. APPLICATION AND ADMINISTRATION

This Standard of Practice shall apply to all naturopathic doctors registered and holding an active naturopath license with the NSCNR (the “**ND Registrant**” or collectively the “**ND Registrants**”).

The administration and application of this Standard of Practice shall be the responsibility of the Registrar. Should the NSCNR become aware of any alleged breach or noncompliance with this Standard of Practice, it may take any action it considers appropriate, including but not limited to:

SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

- a. contacting a Registrant to request the immediate remedy of any suspected breach or non-compliance;
- b. filing a formal complaint under the *Regulated Health Professions Act* regarding the suspected breach or non-compliance as professional misconduct; and/or
- c. immediate suspension or revocation of Reserved practice permit.

3. OBJECTIVES

The objectives of this Standard are to uphold public interest and safety by:

- a) defining the conditions under which ND Registrants may dispense substances and/or drugs for in-office procedural use;
- b) establishing minimum requirements for safe procurement, storage, handling, traceability, documentation, and administration of dispensed substances and/or drugs; and
- c) clarifying boundaries to prevent pharmacy-level dispensing, manufacturing, redistribution, and other activities outside authorized practice.

4. DEFINITIONS

The following terms have the following meanings when used in this Standard of Practice:

Authorized Source means a supplier from which a Registrant may obtain drugs, substances, sterile solutions, and related devices for in-office use, including:

- a) a manufacturer, packager/labeller, importer, distributor, or wholesaler that is authorized under applicable federal and provincial law to sell or distribute the product in Canada; and/or
- b) a pharmacy licensed under provincial law that is authorized to compound and supply compounded preparations (including sterile preparations), in accordance with applicable pharmacy standards and requirements.

Clinic Inventory consists of substances and/or drugs and related supplies obtained and maintained by a Registrant or clinic for in-office use for authorized clinical procedures.

Compounding, as per the Chiropractic and Naturopathy Regulations, compounding means the mixing of 2 or more ingredients, of which at least 1 is a drug, for the purpose of dispensing a drug or drugs, but does not include reconstituting a drug or drugs with only water.

SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

Drug, as per the Chiropractic and Naturopathy Regulations, has the same meaning as in the Food and Drugs Act (Canada) and includes any substance or combination of substances included in a prescription or incorporated in a schedule set out in the NSCNR Bylaws and Appendix A of this standard of Practice.

In-Office Use Dispensing means the selection and provision of a permitted substance incorporated in schedule set out in the NSCNR Bylaws and Appendix A of this standard of Practice or included in a prescription to a specific patient for administration directly to that patient while in-office by the ND Registrant, as part of a procedure during a patient encounter.

ND Registrant means, for the purposes of this standard, a naturopathic doctor registered with the NSCNR and holding an active naturopath license.

Professional Misconduct has the same meaning as set out in the *Regulated Health Professions Act* and includes failing to maintain the standards of practice.

Reserved Practice has the same meaning as set out in the *Chiropractic and Naturopathic Regulations* and means an activity, procedure or service within the scope of practice of naturopathy that:

- a) involves sufficient risk to the public, as determined by the Board;
- b) the Board requires licensed person to meet additional education, additional training or other requirements beyond an entry to practice level to engage in, and;
- c) a licensed person may engage in only with the approval of the registrar and may require a specific permit.

“substance” has the same meaning as set out in the *Chiropractic and Naturopathic Regulations* and means anything, other than a drug, permitted by scope of practice legislation or bylaws, that is publicly available, and which may include botanical tinctures, botanical powders, herbals, extracts, base creams, slaves, ointments, vitamins, minerals, and amino acids.

5. AREAS OF RESERVED PRACTICE PERMITS

Substances and/or drugs dispensed for use in procedures involving Reserved Practices, including Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, and Autologous Blood Products, may only be used where the ND Registrant holds the applicable NSCNR Reserved Practice Permit and meets all training, competence, emergency preparedness, infection prevention and control, and documentation requirements for that activity.

SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

Where the substance or drug requires aseptic preparation of a sterile product before administration, the ND Registrant must also comply with the NSCNR Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products.

6. STANDARDS OF PRACTICE

A. General Requirements to perform In-office Use Dispensing

- a) Dispensing for in-office use is permitted **only** where the Registrant:
 - i. holds an active naturopath license in Nova Scotia;
 - ii. **holds any applicable Reserved Practice Permit(s) where the administration of a dispensed substance involves Reserved Practices** (e.g., Intravenous Therapy, Injection Therapies, PRP, etc. as applicable);
 - iii. dispenses only substances and/or drugs that are consistent with the Registrant's individual training and competency;
 - iv. dispenses only substances and/or drugs that comply with the scope of practice for those holding a naturopath license in Nova Scotia;
- b) Where a substance, drug, sterile solution, sterile preparation, container, device, or closed sterile system is accessed, prepared, mixed, diluted, combined, transferred, or otherwise handled in a manner that constitutes immediate-use compounding or aseptic preparation of sterile products, the Registrant must comply with the NSCNR Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products.

B. In-office Use Dispensing Scope of Authorization

- a) ND Registrants may dispense approved substances and/or drugs for in-office procedural use only where those substances and/or drugs are included on the NSCNR Approved Substances and Drugs for In-Office Use Schedule (Appendix A).
- b) ND Registrants may dispense approved substances and/or drugs that are:
 - i. sterile and obtained from an authorized source, including:
 - (a) a commercially manufactured sterile drug or solution; and/or
 - (b) a sterile preparation compounded and supplied by a licensed pharmacy in accordance with applicable pharmacy compounding standards;
 - ii. authorized for use within naturopathic practice;
 - iii. administered directly to the patient in-office by the Registrant as part of a procedure; and
 - iv. consistent with the Registrant's training, competence, and scope of practice.
- c) A Registrant must not obtain, store, or use substances and/or drugs where:



SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

- i. the integrity of the supply chain is unknown,
- ii. where product authenticity cannot be reasonably verified, or
- iii. where there is reason to believe the product has been compromised (including by improper storage, damage, expiry, or recall).

d) A Registrant must:

- i. obtain substances and/or drugs intended for in-office procedural use only from an Authorized Source and in a manner that maintains product integrity, including compliance with manufacturer storage and handling requirements;
- ii. store substances and/or drugs in accordance with manufacturer requirements (including temperature, light protection, and expiry controls);
- iii. maintain reasonable security and controlled access appropriate to the clinical setting and risk profile;
- iv. maintain a process to segregate expired, recalled, or compromised products from active inventory;
- v. administer compounded injectable solutions within 60 minutes of preparation in accordance with **NSCNR Standard: Immediate-Use Compounding**;
- vi. handle substances and/or drugs in accordance with infection prevention and control principles appropriate to the procedure and setting; and
- vii. where dispensing involves sterile products, sterile preparations, vials, ampoules, syringes, IV bags, closed sterile systems, or other products or devices requiring aseptic access, the Registrant must use aseptic technique and comply with the NSCNR Standard of Practice: Infectious Disease Prevention and Control, the NSCNR Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products, and any applicable procedural or Reserved Practice Permit standard.

C. General Standards

a) ND Registrants dispensing substances and/or drugs in-office must:

- i. comply with all manufacturer instructions for storage, handling, preparation, and administration;
- ii. obtain and document informed consent in accordance with the **NSCNR Standard of Practice: Informed Consent**, including consent specific to:
 - (a) the specific procedure, and
 - (b) the specific substance(s) administered; and
- iii. comply the **NSCNR Standard of Practice: Patient Record Management** and document in the patient record and ensure contemporaneous and accurate recording of specific details related to in-office compounding maintaining

SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

documentation sufficient to support traceability, patient safety follow-up, and quality assurance, including:

- (a) the name of the substance and/or drug provided and administered, including details to support product recall response and follow-up;
 - (b) dose/volume and route of administration;
 - (c) lot number and expiry date;
 - (d) date and time of administration;
 - (e) the procedure performed and clinical indication; and
 - (f) patient response, monitoring, and any adverse events.
- iv. ensure that patients are appropriately monitored with the Registrant available for immediate assistance;
 - v. comply with all components of the **NSCNR Standard – Office Use Compounding**
 - vi. comply with all components of **NSCNR Standard – Emergency Preparedness**.

E. QUALITY ASSURANCE

The NSCNR may request submission of inventory records, training documentation, patient records, procurement documentation, storage logs, emergency protocols, and any other documentation required to demonstrate compliance with this Standard of Practice.

The NSCNR may conduct inspections or audits related to dispensing for in-office procedural use at any time, as determined by NSCNR Regulations and Bylaws.

7. EXEMPTIONS

a) Protocol-Directed At-Home Use of viscum albumn

A Registrant may provide a limited quantity of **viscum albumn (mistletoe)** to a specific patient for Protocol-Directed At-Home Use only where:

- i. the viscum albumn is directly connected to an in-office procedure or treatment with an accompanying patient-specific at-home treatment protocol.
- ii. the initial administration of the viscum albumn occurs in-office;
- iii. the viscum albumn is provided in a sterile, single-use vial, ampoule, single-dose container, or manufacturer-filled device, it is provided unopened and intact for use by the identified patient only;
- iv. the use of viscum albumn is within the individual Registrant's scope of practice, individual competence, and any applicable Reserved Practice Permit area(s);
- v. the quantity provided is limited to the amount reasonably required for the patient-specific protocol;
- vi. the Registrant provides patient-specific instructions for use, storage, precautions, adverse events, and when to seek medical care;

SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

- vii. the Registrant documents the clinical indication, source of the protocol, quantity, directions for use, lot number and expiry date, and follow-up plan; and
- viii. the provision does not constitute pharmacy-level dispensing, retail sale, redistribution, wholesaling, or ongoing supply outside of the protocol.

- b) This standard does not apply to manufactured retail products available in the public domain which are governed under NSCNR Standards of Practice – Retail Sales.

8. RESTRICTIONS

This standard **does not permit** ND Registrants to:

- i. operate a pharmacy or provide pharmacy-level dispensing services, or engage in activities that constitute operating or performing functions of a pharmacy or drug distribution service;
- ii. engage in redistribution, wholesaling, or supply of drugs or sterile solutions to other clinics, practitioners, or third parties;
- iii. dispense, supply, or administer substances and/or drugs other than for in-office procedural use;
- iv. dispense, supply, or administer substances and/or drugs outside the Registrant’s individual competence, training, scope of practice, or any applicable Reserved Practice Permit area(s) or the NSCNR approved Substances and Drugs for In-Office use schedule in Appendix A; or
- v. use substances and/or drugs where authenticity, storage conditions, or product integrity cannot be reasonably verified.

9. LEGISLATIVE CONTEXT

[Regulated Health Professions Act \(2023\)](#)

[Regulated Health Professions General Regulations](#)

Regulations Respecting Chiropractic and Naturopathy

Nova Scotia Chiropractic and Naturopathic Regulator Bylaws

10. ADDITIONAL RELEVANT STANDARDS OF PRACTICE:

Registrants are advised that all NSCNR Standards of Practice apply, including but not limited to, specific application of:

- Patient Record Management
- Retail Sales
- Informed Consent



SP- ND002
Standard of Practice: In Office Use Dispensing
Approved Date: effective May 27, 2026
Amended:
Next Review Date: 2029

- Emergency First Aid
- Emergency Preparedness
- Infectious Disease Prevention and Control
- Immediate-Use Compounding
- Intravenous Therapy
- Injection Therapies
- Autologous Blood Products

Schedule A - Approved Substances and Drugs for Immediate In-Office Use

Interpretation

Inclusion of a substance or drug on this Schedule does not, on its own, authorize a Registrant to obtain, possess, prepare, compound, dispense, or administer that substance or drug. The Registrant must also comply with all applicable legislation, NSCNR Standards of Practice, scope of practice requirements, Reserved Practice Permit requirements, manufacturer instructions, and individual competency requirements.

Where a substance appears with more than one route of administration, only those routes within the Registrant's authority, applicable permit, and competence may be used.

All substances and drugs listed in this Schedule are for immediate in-office use only, unless otherwise specified.

Part 1 - IV Nutrients, Amino Acids, Vitamins, and Minerals

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Amino Acid	Acetylcysteine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Adenosine monophosphate	IV	IV nutrient infusion	
Nutraceutical	Adenosine triphosphate	IV	IV nutrient infusion	
Amino Acid	Alanine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Alpha Lipoic Acid	IV	IV nutrient infusion	
Amino Acid	Arginine	IV	IV nutrient infusion	Must be used with other amino acids.
Vitamin	Ascorbic Acid (Vitamin C)	IV	IV nutrient infusion	
Amino Acid	Aspartic Acid	IV	IV nutrient infusion	Must be used with other amino acids.
Vitamin	Vitamin B1 (Thiamine)	IV or IM injection	IV/IM nutrient therapy	
Vitamin	Vitamin B2 (Riboflavin)	IV or IM injection	IV/IM nutrient therapy	
Vitamin	Vitamin B3 (Niacinamide)	IV or IM	IV/IM nutrient therapy	
Vitamin	Vitamin B5 (Pantothenic Acid)	IV or IM	IV/IM nutrient therapy	
Vitamin	Vitamin B6 (Pyridoxine)	IV or IM	IV/IM nutrient therapy	

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Vitamin	Vitamin B12 in all forms	IV or IM or SC injection	IV/IM/SC nutrient therapy	
Vitamin	Biotin	IV	IV nutrient infusion	
Mineral	Calcium Chloride	IV	IV mineral therapy	
Nutraceutical	Calcium EDTA	IV	In-office procedural use	
Mineral	Calcium Gluconate	IV	IV mineral therapy	
Mineral	Calcium Glycerophosphate	IV	IV mineral therapy	
Nutraceutical	Choline	IV or IM	IV/IM nutrient therapy	
Mineral	Chromium	IV	IV mineral therapy	
Mineral	Copper Sulfate	IV	IV mineral therapy	
Mineral	Copper II Chloride	IV	IV mineral therapy	
Vitamin	Folate in all forms	IV or IM injection	IV/IM nutrient therapy	
Amino Acid	Glutamine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Glutamic Acid	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Glutathione	IV or IM	IV/IM nutrient therapy	
Amino Acid	Glycine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Histidine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Inositol	IV or IM	IV/IM nutrient therapy	
Amino Acid	Isoleucine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	L-Tryptophan	IV	IV nutrient infusion	
Amino Acid	Leucine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Levocarnitine and its salts	IV	IV nutrient infusion	

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Amino Acid	Lysine	IV or IM	IV/IM nutrient therapy	Must be used with other amino acids.
Mineral	Magnesium Sulfate	IV or IM	IV/IM mineral therapy	
Mineral	Magnesium Chloride	IV or IM	IV/IM mineral therapy	
Mineral	Manganese	IV	IV mineral therapy	
Nutraceutical	Methionine	IV or IM	IV/IM nutrient therapy	
Mineral	Molybdenum	IV	IV mineral therapy	
Nutraceutical	MSM	IV	IV nutrient infusion	
Nutraceutical	Nicotinamide Adenine Dinucleotide	IV or SC injection	IV/SC nutrient therapy	
Amino Acid	Ornithine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Phenylalanine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Phosphatidylcholine	IV	IV nutrient infusion	
Mineral	Potassium Chloride	IV	IV mineral therapy	Not more than 0.3 mEq/kg/hr; may not be administered on its own or by IV push.
Mineral	Potassium Phosphate	IV	IV mineral therapy	Not more than 0.3 mEq/kg/hr; may not be administered on its own or by IV push.
Amino Acid	Proline	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Selenium	IV	IV mineral therapy	
Amino Acid	Serine	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Sodium Bicarbonate	IV	IV mineral / buffer therapy	
Mineral	Sodium Iodide	IV	IV mineral therapy	Must be used with other minerals.
Mineral	Strontium and its salts	IV	IV mineral therapy	

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Amino Acid	Taurine	IV	IV nutrient infusion	
Amino Acid	Threonine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Tyrosine	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Vanadium	IV	IV mineral therapy	
Vitamin	Vitamin A	IV or IM	IV/IM vitamin therapy	
Vitamin	Vitamin D	IV or IM	IV/IM vitamin therapy	
Vitamin	Vitamin E	IV	IV vitamin therapy	
Vitamin	Vitamin K1	IM	IM vitamin therapy	
Mineral	Zinc Chloride	IV	IV mineral therapy	
Mineral	Zinc Sulphate	IV	IV mineral therapy	

Part 2 - IV Fluids and Injection Fluids

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
IV Fluid	Dextrose	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	
Injection Fluid	Dextrose D50W	Intra-articular	Prolotherapy	
IV Fluid	Lactated Ringer's Solution	IV	IV fluid therapy	
Injection Fluid	Mannitol 25%	SC	Perineural injection fluid	
IV Fluid	Ringer's Solution (sodium, chloride, potassium and calcium)	IV	IV fluid therapy	
IV Fluid	Saline Solution	IV	IV fluid therapy	
IV Fluid	Sodium Chloride	IV	IV fluid therapy	IV with MAH.

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Mineral	Sodium Citrate	SC, IM, IV, intra-articular	In-office procedural use	
IV Fluid	Sterile Water	IV	IV fluid therapy	Isotonic - must become hypertonic before injection.

Part 3 - Iron Preparations

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Iron	Ferric derisomaltose	IV	In-office iron infusion	
Iron	Ferric gluconate	IV	In-office iron infusion	
Mineral	Ferrous Sulphate	IM	Iron therapy	Use Z track.
Iron	Iron sucrose	IV	In-office iron infusion	
Iron	Saccharated Iron Oxide	IV	In-office iron infusion	Product-specific entry.
Iron	Ferric Sodium Gluconate Complex	IV	In-office iron infusion	Product-specific entry.
Iron	Ferric Derisomaltose	IV	In-office iron infusion	Product-specific entry.

Part 4 - Corticosteroids and Procedural Injection Medications

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Medication / Corticosteroid	Betamethasone	IM or intra-articular	In-office corticosteroid injection	
Medication	Bupivacaine	IM	In-office procedural use	
Medication / Corticosteroid	Dexamethasone	IM and intra-articular	In-office corticosteroid injection	

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Medication	Heparin	SC, IM, IV, intra-articular	In-office procedural use	Limited for use with PRP and MAH/Ozone with associated Reserved Practice Permit
Nutraceutical	Hyaluronidase	SC	In-office procedural use	
Medication / Corticosteroid	Hydrocortisone	IM and intra-articular	In-office corticosteroid injection	
Medication	Lidocaine	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	
Nutraceutical	Methylene Blue	IV	In-office procedural use	
Medication / Corticosteroid	Methylprednisolone / Methylprednisolone acetate	IM or intra-articular	In-office corticosteroid injection	
Medication	Ondansetron	IV	Nausea	
Nutraceutical	Phosphatidylcholine with Deoxycholate	SC	In-office procedural use	
Medication	Procaine	SC, IM, IV, intra-articular, extra-articular, intradermal	In-office procedural use	
Medication / Corticosteroid	Triamcinolone acetonide / Triamcinolone hexacetonide	IM and intra-articular	In-office corticosteroid injection	
Corticosteroids	Methylprednisolone acetate (Depo-Medrol®)	IM or intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Triamcinolone acetonide (Kenalog®)	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Triamcinolone hexacetonide (Aristospan® / Trispan®)	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Betamethasone (Celestone Soluspan®)	IM or intra-articular	In-office corticosteroid injection	Product-specific entry.

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Corticosteroids	Dexamethasone	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Hydrocortisone	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.

Part 5 - Viscosupplementation / Hyaluronan Products

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Nutraceutical / Hyaluronan	Hyaluronic Acid	IV and intra-articular	In-office viscosupplementation / procedural use	
Hyaluronan / Viscosupplementation	Durolane	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Cingal	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Monovisc	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Synvisc / Synvisc-One	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Orthovisc	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	SportVis	Intra-articular	In-office viscosupplementation injection	Product-specific entry.

SP- ND002

Standard of Practice: In Office Use Dispensing

Approved Date: effective May 27, 2026

Amended:

Next Review Date: 2029

Part 6 - Emergency Medications

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Emergency Medication	Atropine	IV	In-office emergency use	For use only during in-office emergency.
Emergency Medication	Diphenhydramine Hydrochloride	IV or IM	In-office emergency use	For use only during in-office emergency.
Emergency Medication	Epinephrine Hydrochloride	IM or SC	In-office emergency use	For use only during in-office emergency.

Part 7 - Biologics / Specialized Procedures

Drug / Substance Class	Name of Substance	Permitted Route(s) of Administration	Permitted In-Office Purpose	Additional Information
Other	Autologous blood products (PRP)	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	Requires applicable Reserved Practice Permit.
Nutraceutical	DMPS	IV	In-office procedural use	
Nutraceutical	DMSA	IV	In-office procedural use	
Nutraceutical	DMSO	IV	In-office procedural use	
Nutraceutical	EDTA	IV	In-office procedural use	
Nutraceutical	Hydrochloric Acid	IV	In-office procedural use	
Nutraceutical	Hydrogen Peroxide 3%	IV	In-office procedural use	
Other	Ozone	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	Requires applicable Reserved Practice Permit.
Nutraceutical	Viscum Album	IV or SC injection or intra-articular	In-office procedural use	Used for arthritis.